NASDAQ:XBIT XBiotech Q1 2026 Earnings Report $2.19 +0.01 (+0.46%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$2.18 -0.01 (-0.46%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast XBiotech EPS ResultsActual EPS-$0.18Consensus EPS $0.03Beat/MissMissed by -$0.21One Year Ago EPSN/AXBiotech Revenue ResultsActual RevenueN/AExpected Revenue$7.00 millionBeat/MissN/AYoY Revenue GrowthN/AXBiotech Announcement DetailsQuarterQ1 2026Date5/14/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile XBiotech Earnings HeadlinesXBiotech (NASDAQ:XBIT) Stock Price Crosses Below 50-Day Moving Average - What's Next?September 15, 2026 | americanbankingnews.comXBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial SpondyloarthritisJune 15, 2026 | globenewswire.comThe hidden costs of a hands-off retirement accountContributing to your 401(k) consistently is good financial behavior - but contributing and optimizing are two different things. High fees, heavy company stock concentration, and target-date funds that follow a formula rather than your situation can quietly erode your balance over time. 74% of U.S. millionaires work with a financial advisor - more than double the general population rate. A fiduciary advisor can review your 401(k) for fees, allocation, and alignment with your actual timeline. SmartAsset's free quiz matches nearly 50,000 people each month with vetted fiduciary advisors in their area. | SmartAsset (Ad)XBiotech’s New Axial Spondyloarthritis Trial Puts Vilamakitug on Investors’ RadarMay 14, 2026 | tipranks.comXBiotech: Q4 Earnings SnapshotMarch 13, 2026 | chron.comXBiotech’s New Trial: A Potential Game-Changer for Rheumatoid Arthritis Treatment?October 28, 2025 | msn.comSee More XBiotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like XBiotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XBiotech and other key companies, straight to your email. Email Address About XBiotechXBiotech (NASDAQ:XBIT) is a biotechnology company focused on developing therapies that target inflammation and other disease processes. The company’s technology platform is based on “True Human” monoclonal antibodies, which are derived from naturally occurring human antibodies rather than genetically engineered or animal-derived antibody sequences. XBiotech’s research has included bermekimab, a fully human antibody designed to neutralize interleukin-1 alpha, an inflammatory protein associated with cancer, autoimmune conditions and other diseases. The company has evaluated bermekimab in clinical studies involving cancer and inflammatory disorders, while continuing to research additional antibody-based treatments and potential applications. Founded in 2005 and headquartered in Austin, Texas, XBiotech has pursued the discovery, development and potential commercialization of biological therapies for patients in the United States and international markets. John Simard, the company’s founder, has served as its chairman and chief executive officer.View XBiotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusPriced for a Pullback or More Gains? These 3 Stocks Are Testing the LimitsCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and Scale Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
